The study, sponsored by the Masonic Cancer Center at the University of Minnesota, aimed to assess the safety and microbiome effects of oral activated charcoal in lung cancer patients undergoing a specific surgical procedure (TEMLA). However, the trial has been withdrawn due to logistical challenges and product availability. This withdrawal may indicate potential hurdles in the commercialization of OAC for this indication, as well as the need for further exploration of its clinical utility in solid tumors before considering hematologic malignancies. The market for supportive care in oncology is significant, but the competitive landscape includes established therapies and emerging agents targeting similar patient populations. Further diligence is required to assess the viability of OAC in this context and its potential integration into standard care protocols.